Free tool
FAERS Monitor: Cervidil
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 020411 or its brand name (Cervidil, Dinoprostone). Reports on generic versions are filed under their own applications.
Reports
769
Serious
660
86% of reports
Hospitalization
202
Death reported
46
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- foetal exposure during pregnancy127
- drug exposure during pregnancy70
- exposure during pregnancy70
- caesarean section63
- maternal exposure during pregnancy58
- premature separation of placenta47
- off label use44
- uterine hyperstimulation41
- drug ineffective36
- premature baby35
- haemoglobin decreased33
- premature delivery33
- white matter lesion30
- uterine hypertonus28
- hypospadias26
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 9 |
| 2005 | 8 |
| 2006 | 24 |
| 2007 | 10 |
| 2008 | 29 |
| 2009 | 9 |
| 2010 | 5 |
| 2011 | 18 |
| 2012 | 15 |
| 2013 | 21 |
| 2014 | 13 |
| 2015 | 18 |
| 2016 | 36 |
| 2017 | 50 |
| 2018 | 58 |
| 2019 | 39 |
| 2020 | 46 |
| 2021 | 54 |
| 2022 | 66 |
| 2023 | 95 |
| 2024 | 54 |
| 2025 | 54 |
| 2026 | 38 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,390 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| uterine hyperstimulationSignal | 41 | 18401.4 | 12465.5 | 440,210 |
| uterine hypertonusSignal | 28 | 3154.6 | 2147.2 | 76,351 |
| premature separation of placentaSignal | 47 | 861.9 | 650.3 | 38,352 |
| white matter lesionSignal | 30 | 665.6 | 466.6 | 18,793 |
| hypospadiasSignal | 26 | 346.2 | 236.7 | 8,501 |
| caesarean sectionSignal | 63 | 148.7 | 117.3 | 9,053 |
| premature deliverySignal | 33 | 56.8 | 40.7 | 1,751 |
| drug exposure during pregnancySignal | 70 | 56.4 | 45.1 | 3,753 |
| foetal exposure during pregnancySignal | 127 | 42.8 | 36.5 | 5,155 |
| premature babySignal | 35 | 31.8 | 23.0 | 1,015 |
| exposure during pregnancySignal | 70 | 30.8 | 24.7 | 1,995 |
| maternal exposure during pregnancySignal | 58 | 17.8 | 13.9 | 907 |
| haemoglobin decreasedSignal | 33 | 8.8 | 6.3 | 221 |
| off label use | 44 | 1.4 | 1.0 | 4 |
| drug ineffective | 36 | 0.7 | 0.5 | 3 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.